Primary mediastinal lymphoma: diagnosis and treatment options

References

• Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory Committee Meeting – Airlie House, Virginia, November 1997. J Clin Oncol 1999;17(12):3835-49
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer; Lyon, France: 2008
   Google Scholar
• Levitt LJ, Aisenberg AC, Harris NL, et al. Primary Non-Hodgkin’s lymphoma of the mediastinum. Cancer 1982;50(11):2486-92
   PubMedGoogle Scholar
• Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (Groupe d’Etude des Lymphomes de l’Adulte) study. Am J Surg Pathol 1996;20(7):877-88
   PubMedGoogle Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16(8):2780-95
   PubMed Web of Science ®Google Scholar
• Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 1986;10(4):379-90
   PubMedGoogle Scholar
• Hofmann WJ, Momburg F, Moller P, Otto HF. Intra- and extrathymic B cells in physiologic and pathologic conditions. Immunohistochemical study on normal thymus and lymphofollicular hyperplasia of the thymus. Virchows Arch A Pathol Anat Histopathol 1988;412(5):431-42
   Google Scholar
• Copie-Bergman C, Gaulard P, Maouche-Chretien L, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood 1999;94(10):3567-75
   PubMedGoogle Scholar
• Möller P, Lämmler B, Eberlein-Gonska M, et al. Primary mediastinal clear cell lymphoma. Virchows Archiv A 1986;409(1):79-92
   Web of Science ®Google Scholar
• Paulli M, Strater J, Gianelli U, et al. Mediastinal B-cell lymphoma: a study of its histomorphologic spectrum based on 109 cases. Hum Pathol 1999;30(2):178-87
   PubMedGoogle Scholar
• Barth TF, Leithauser F, Joos S, et al. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol 2002;3(4):229-34
   PubMedGoogle Scholar
• Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005;29(11):1411-21
   PubMed Web of Science ®Google Scholar
• Pileri SA, Gaidano G, Zinzani PL, et al. Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins. Am J Pathol 2003;162(1):243-53
   PubMed Web of Science ®Google Scholar
• Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol 2004;202(1):60-9
   PubMedGoogle Scholar
• de Leval L, Ferry JA, Falini B, et al. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol 2001;25(10):1277-82
   PubMedGoogle Scholar
• Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002;15(11):1172-80
   PubMedGoogle Scholar
• Millan J, Alonso MA. MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Eur J Immunol 1998;28(11):3675-84
   PubMedGoogle Scholar
• Rodig SJ, Savage KJ, LaCasce AS, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 2007;31(1):106-12
   PubMedGoogle Scholar
• Jaffe ES, Stein H, Campo E, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues. Swerdlow SH, Campo E, Harris NL, et al. International Agency for Research on Cancer; Lyon, France; 2008. 267-8
   Google Scholar
• Calaminici M, Piper K, Lee AM, Norton AJ. CD23 expression in mediastinal large B-cell lymphomas. Histopathology 2004;45(6):619-24
   PubMedGoogle Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503-11
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198(6):851-62
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102(12):3871-9
   PubMed Web of Science ®Google Scholar
• Joos S, Küpper M, Ohl S, et al. Genomic Imbalances Including Amplification of the Tyrosine Kinase Gene JAK2 in CD30+ Hodgkin Cells. Cancer Res 2000;60(3):549-52
   PubMed Web of Science ®Google Scholar
• Joos S, Otano-Joos MI, Ziegler S, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996;87(4):1571-8
   PubMed Web of Science ®Google Scholar
• Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014;46(4):329-35
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010;116(17):3268-77
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368(2):161-70
   PubMed Web of Science ®Google Scholar
• Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118(10):2659-69
   PubMed Web of Science ®Google Scholar
• Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471(7338):377-81
   PubMed Web of Science ®Google Scholar
• Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 2014;20(10):2674-83
   PubMed Web of Science ®Google Scholar
• Ritz O, Moller P, Ushmorov A. Targeting the intratumor heterogeneity in PMBL. Cell Cycle 2014;13:15
   PubMedGoogle Scholar
• Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 1988;62(9):1893-8
   PubMed Web of Science ®Google Scholar
• Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995;89(4):780-9
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993;11(12):2306-13
   PubMedGoogle Scholar
• Bishop PC, Wilson WH, Pearson D, et al. CNS involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 1999;17(8):2479-85
   PubMed Web of Science ®Google Scholar
• Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol 1993;11(7):1336-43
   PubMed Web of Science ®Google Scholar
• Lamarre L, Jacobson JO, Aisenberg AC, Harris NL. Primary large cell lymphoma of the mediastinum. A histologic and immunophenotypic study of 29 cases. Am J Surg Pathol 1989;13(9):730-9
   PubMed Web of Science ®Google Scholar
• Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol 1999;17(3):784-90
   PubMed Web of Science ®Google Scholar
• Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood 2014;124(10):1563-9
   PubMed Web of Science ®Google Scholar
• Elia S, Cecere C, Giampaglia F, Ferrante G. Mediastinoscopy vs. anterior mediastinotomy in the diagnosis of mediastinal lymphoma: a randomized trial. Eur J Cardiothorac Surg 1992;6(7):361-5
   PubMedGoogle Scholar
• Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005;130(5):691-9
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15(4):1646-53
   PubMed Web of Science ®Google Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17(1):123-30
   PubMed Web of Science ®Google Scholar
• Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90(2):372-6
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002;87(12):1258-64
   PubMed Web of Science ®Google Scholar
• Martelli MP, Martelli M, Pescarmona E, et al. MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Ann Oncol 1998;9(9):1027-9
   PubMedGoogle Scholar
• Zinzani PL, Martelli M, Bendandi M, et al. Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica 2001;86(2):187-91
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999;94(10):3289-93
   PubMed Web of Science ®Google Scholar
• Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22(3):664-70
   PubMed Web of Science ®Google Scholar
• Avigdor A, Sirotkin T, Kedmi M, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 2014;93(8):1297-304
   PubMedGoogle Scholar
• Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014;55(3):538-43
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009;9(5):381-5
   PubMedGoogle Scholar
• Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17(2):239-49
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368(15):1408-16
   PubMed Web of Science ®Google Scholar
• Mazzarotto R, Boso C, Vianello F, et al. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys 2007;68(3):823-9
   PubMedGoogle Scholar
• De Sanctis V, Finolezzi E, Osti MF, et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. Int J Radiat Oncol Biol Phys 2008;72(4):1154-60
   PubMed Web of Science ®Google Scholar
• Martelli M, Zucca E, Gospodarowicz M, et al. A randomized multicenter, two arm, phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B cell lymphoma (PMBCL): The IELSG 37 study. In: Oral presentations. Wiley J, Sons L, Hematological Oncology 2013. 140
   Google Scholar
• Mikhaeel NG, Timothy AR, O’Doherty MJ, et al. 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin’s Lymphoma-Comparison with CT. Leuk Lymphoma 2000;39(5-6):543-53
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19(2):414-19
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91(5):850-4
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579-86
   PubMed Web of Science ®Google Scholar
• Meignan M, Barrington S, Itti E, et al. Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3-5 October 2012. Leuk Lymphoma 2014;55(1):31-7
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Hamlin PAJr, Maragulia J, et al. Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01-142) without radiotherapy for patients with primary mediastinal large B cell lymphoma. In: ASH Annual Meeting Abstracts. 2010. 420
   Google Scholar
• Savage KJ, Yenson PR, Shenkier T, et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. In: ASH Annual Meeting Abstracts. 2012. 303
   Google Scholar
• Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys 2013;87(2):311-16
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Broccoli A, Casadei B, et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014;32(17):1769-75
   PubMed Web of Science ®Google Scholar
• Ceriani L, Zucca E, Zinzani PL, et al. Prognostic value of 18FDG baseline functional PET parameters in primary mediastinal diffuse large B-cell lymphoma. In: Poster presentations. Oncology H, Hematological Oncology 2013. 151-200
   Google Scholar
• Han HS, Escalon MP, Hsiao B, et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Ann Oncol 2009;20(2):309-18
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A, et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol 2008;26(3):171-8
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Pintilie M, Tsang R, et al. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49(7):1329-36
   PubMed Web of Science ®Google Scholar
• Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998;91(2):717-23
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184-90
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• Bryan LJ, Gordon LI. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Study of nivolumab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have either failed or are not eligible for autologous stem cell transplant (CheckMate 139). Available from: http://clinicaltrials.gov/ct2/show/NCT02038933
   Google Scholar